Evidence map›Paper›PMID 37656362›Full record

ArticleActa neurologica Belgica2023

Genetic, serological and clinical evaluation of childhood myasthenia syndromes- single center subgroup analysis experience in Turkey.

Özlem Özsoy, Tayfun Cinleti, Çağatay Günay, Gamze Sarıkaya Uzan, Özlem Giray Bozkaya, Ahmet Okay Çağlayan, Semra Hız Kurul, Uluç Yiş

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neurologica Belgica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Özlem ÖzsoyDepartment of Pediatric Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey. drozlemozsoypediatri@gmail.com.ORCID http://orcid.org/0000-0001-8552-0504
Tayfun CinletiDepartment of Pediatric Genetics, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey.ORCID http://orcid.org/0000-0001-9041-1820
Çağatay GünayDepartment of Pediatric Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey.ORCID http://orcid.org/0000-0001-7860-6297
Gamze Sarıkaya UzanDepartment of Pediatric Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey.ORCID http://orcid.org/0000-0002-5028-9995
Özlem Giray BozkayaDepartment of Pediatric Genetics, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey.ORCID http://orcid.org/0000-0003-1455-308X
Ahmet Okay ÇağlayanDepartment of Medical Genetics, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey.ORCID http://orcid.org/0000-0002-2332-322X
Semra Hız KurulDepartment of Pediatric Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey.ORCID http://orcid.org/0000-0002-8020-4884
Uluç YişDepartment of Pediatric Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey.ORCID http://orcid.org/0000-0001-8355-1411
Dokuz Eylül University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCongenital myasthenic syndrome is a disease that occurs due to several types such as mutations in different pre-synaptic, synaptic, post-synaptic proteins and, glycosylation defects associated with congenital myopathy. Juvenile myasthenia gravis is an autoimmune condition usually caused by antibodies targeting the acetylcholine receptor.

aimsOur objective is to conduct an analysis on the subgroup traits exhibited by patients who have been diagnosed with congenital myasthenic syndrome and juvenile myasthenia gravis, with a focus on their long-term monitoring and management.

methodsThis study was conducted on children diagnosed with myasthenia gravis, who were under the care of Dokuz Eylul University's Department of Pediatric Neurology for a period of ten years.

resultsA total of 22 (12 congenital myasthenic syndrome, 10 juvenile myasthenia gravis) patients were identified. Defects in the acetylcholine receptor (6/12) were the most common type in the congenital myasthenic syndrome group. Basal-lamina-related defects (5/12) were the second most prevalent. One patient had a GFPT1 gene mutation (1/12). Patients with ocular myasthenia gravis (n = 6) exhibited milder symptoms. In the generalized myasthenia gravis group (n = 4), specifically in postpubertal girls, a more severe clinical progression was observed, leading to the implementation of more aggressive treatment strategies.

conclusionThis study highlights that clinical recognition of congenital myasthenic syndrome and knowledge of related genes will aid the rapid diagnosis and treatment of these rare neuromuscular disorders. Findings in the juvenile myasthenia gravis group demonstrate the impact of pubertal development and the need for timely and appropriate active therapy, including thymectomy, to improve prognosis.

Indexed as

Myasthenia GravisMyasthenic Syndromes, CongenitalChildFemaleHumansMuscle WeaknessReceptors, CholinergicTurkeyReceptors, CholinergicAntibodyCongenital myasthenic syndromesGeneticJuvenile myasthenia gravisThymectomyTurkey

Identifiers

PMID37656362
OpenAlexW4386347100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.